Cerebain Biotech Corp. Appoints Dr. Saini Chairman of Its Scientific Advisory Board

Cerebain Biotech Corp. Appoints Dr. Saini Chairman of Its Scientific Advisory Board

DALLAS--(BUSINESS WIRE)-- Cerebain Biotech Corp. (“Cerebain” or “the Company”), a subsidiary of Discount Dental Materials, Inc. (OTCBB: DDOO) announced today the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company’s efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer’s disease. Dr. Saini is the lead scientist behind the development of the world's first medical device specifically designed for the treatment of Alzheimer’s disease utilizing the Omentum.

Dr. Surinder Saini is Board-certified Gastroenterologist practicing in Orange County, California since 1992. He started his academic journey with merit scholarship from high school to medical college. His quest for knowledge led to his receiving distinctions in Pharmacology, Medicine and Clinical Medicine. After residency at New York Medical College, he received a Gastroenterology Fellowship at the prestigious Mount Sinai School of Medicine (Beth Israel Program), New York, NY. He has kept keen interest in clinical research. His interest in cutting edge technology led to a documentary on National Japanese TV covering capsule endoscopy technology. He has been awarded "doctor of the month" and "Gastroenterology doctor of the year" by Hoag Memorial Hospital in Newport Beach.

“I have enjoyed the process of working with the Cerebain Biotech Team thus far and look forward to the promise of our ultimate success,” said Dr. Saini. “I believe that our unique Omentum methodology for Alzheimer’s patients has a great potential to reverse the effects of this debilitating disease.”

“Having worked closely with this world class physician for some time, we are delighted to formally announce the appointment of Dr. Saini as Chairman of our Scientific Advisory Board,” said Eric Clemons, President of Cerebain Biotech. “Our team at Cerebain looks forward to working closely with Dr. Saini, and will be looking at adding additional Physicians and Scientists to our Scientific Advisory Board in the near future.”

About Discount Dental Materials, Inc.

Discount Dental Materials, Inc. was incorporated in Nevada on December 17, 2007. The Company’s business involves the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The Company’s planned products include both a medical device solution as well as a synthetic drug solution. The Company’s operations are conducted through its wholly-owned subsidiary, Cerebain Biotech Corp. For more information about Discount Dental and Cerebain Biotech, please visit the Company’s website at and, under the ticker symbol “DDOO”, to view the Company’s public filings and stock quote.

Forward-Looking Statements

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe,” "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.

Discount Dental Materials, Inc.
Mr. Eric Clemons, 949-415-7478

KEYWORDS:   United States  North America  California  Texas


Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2494003, ~/Articles/ArticleHandler.aspx, 10/9/2015 10:18:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...